Get started
Author

Roxana Draghici

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer
2019 · Petra Seibold, Adam Webb, et al. · Radiotherapy and Oncology · 110
PDF
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study
2022 · Morgan Michalet, Karl Bordeau, et al. · Frontiers in Oncology · 42
PDF
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study
2022 · Karl Bordeau, Morgan Michalet, et al. · Cancers · 36
PDF
Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study
2022 · Morgan Michalet, Olivier Riou, et al. · Cancers · 26
PDF
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study
2023 · Karl Bordeau, Morgan Michalet, et al. · Journal of Clinical Medicine · 22
PDF
Stereotactic MR-Guided Radiotherapy for Adrenal Gland Metastases: First Clinical Results
2022 · Morgan Michalet, Ons Bettaïeb, et al. · Journal of Clinical Medicine · 22
PDF
Magnetic Resonance–Guided Reirradiation for Local Recurrence Within the Prostate or in the Prostate Bed: Preliminary Results of a Prospective Registry Study
2021 · Morgan Michalet, Olivier Riou, et al. · Advances in Radiation Oncology · 16
A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors
2023 · Karl Bordeau, Morgan Michalet, et al. · Radiotherapy and Oncology · 15
Magnetic resonance guided stereotactic reirradiation for locally recurrent prostate cancers: Long-term results from a prospective registry study
2025 · Chloé Buchalet, Olivier Riou, et al. · Radiotherapy and Oncology · 7
PDF
Efficacy, safety, and feasibility of volumetric modulated arc therapy for synchronous bilateral breast cancer management
2022 · Stanislas Quesada, Pascal Fenoglietto, et al. · Frontiers in Oncology · 4
Long-term fatigue based on the EORTC QLQ-C30 up to five years after radiotherapy and its trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study
2026 · Philipp Heumann, Juan C. Rosas, et al. · British Journal of Cancer
PDF
Data from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Table 4 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Table 3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Supplementary Table S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Supplementary Appendix S1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Figure 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Supplementary Table S2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Table 2 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Supplementary Table S3 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Supplementary Table S4 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Table 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Figure 1 from Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al.
Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
2026 · Adam J. Webb, Emily Harper, et al. · Clinical Cancer Research
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients
2026 · Philipp Heumann, Miguel E. Aguado-Barrera, et al. · Nature Communications
PDF
Works count: 25
Citation count: 300
H-index: 8
I10-index: 8
Year
Topic
Type